Palmetto Expands Coverage for Decipher Biosciences Prostate Cancer Test

Decipher Biosciences announced Friday its Decipher Prostate test received expanded coverage from Medicare Administrative Contractor Palmetto GBA.

Decipher Prostate, which includes Decipher Prostate Biopsy and Decipher Prostate RP, will be covered for all men with localized prostate cancer being considered for treatment. For initial treatment, the local coverage determination covers men in very low through very high and pelvic lymph node positive National Comprehensive Cancer Network risk groups, the company said. Patients must have a life expectancy of at least 10 years and cannot have received pelvic radiation or androgen deprivation therapy prior to the biopsy or prostate resection specimen.

In December, Palmetto announced a final LCD covering the Decipher Prostate Biopsy test in men diagnosed with favorable or unfavorable intermediate-risk prostate cancer. That LCD will likely be retired in November, before the new one goes into effect. 

Source: https://www.genomeweb.com/reimbursement-news/palmetto-expands-coverage-decipher-biosciences-prostate-cancer-test